Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation.
Anti-VEGF
Compliance
Macular degeneration
Nonpersistence
Vision loss
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
08
11
2021
accepted:
05
01
2022
pubmed:
21
1
2022
medline:
21
1
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
We aimed to evaluate visual and anatomical outcomes among eyes with neovascular age-related macular degeneration (nAMD) that were persistent to intravitreal aflibercept therapy compared to those that were nonpersistent to therapy. We audited 648 treatment-naïve eyes of 559 patients regarding visual acuity (VA) given as the logarithm of the minimum angle of resolution (logMAR) and anatomic outcomes at baseline and at each subsequent follow-up visit for up to 5 years. Nonpersistence was defined as a visit-free interval of > 6 months. Among the enrolled eyes, 405 were persistent to the therapy and 243 (37%) were nonpersistent, of which 161 (66%) eyes returned for further therapy after a gap of clinical care. In the nonpersistent group, we observed a decline from 0.58 ± 0.35 to 0.92 ± 0.57 logMAR (p = 0.01) after 60 months. Compared with the persistent group, the nonpersistent group had worse visual outcomes at their 33-month (p = 0.03), 42-month (p = 0.01), 51-month (p = 0.001) and 60-month (p = 0.01) visits. Additionally, 5/405 (1.2%) eyes in the persistent group and 8/161 (5.0%) eyes in the nonpersistent group developed an end-stage disease with a subfoveal fibrosis during the observational period (p = 0.013). We found that eyes with nAMD that were nonpersistent to intravitreal aflibercept therapy experienced statistically significantly worse VA compared to eyes persistent to therapy within 3 years. Moreover, eyes in the nonpersistent group had a four-fold higher risk of developing a fovea-involving fibrosis. Considering the potential irreversible deterioration with respect to best-corrected VA within nAMD, strategies need to be developed for patients at risk of nonpersistence to therapy.
Identifiants
pubmed: 35048330
doi: 10.1007/s40123-022-00452-8
pii: 10.1007/s40123-022-00452-8
pmc: PMC8769092
doi:
Types de publication
Journal Article
Langues
eng
Pagination
559-571Informations de copyright
© 2022. The Author(s).
Références
Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.
doi: 10.1016/j.ophtha.2012.09.006
Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.e5.
doi: 10.1016/j.ophtha.2008.10.018
Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418–31.
doi: 10.1097/IAE.0000000000001142
Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–6.
doi: 10.1136/bjophthalmol-2014-305327
Holz FG, Bandello F, Gillies M, Mitchell P, Osborne A, Sheidow T, et al. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol. 2013;97:1161–7.
doi: 10.1136/bjophthalmol-2013-303232
Obeid A, Gao X, Ali FS, Aderman CM, Shahlaee A, Adam MK, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol. 2018;136:1251–9.
doi: 10.1001/jamaophthalmol.2018.3578
Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration. Ophthalmology. 2021;128:234–47.
doi: 10.1016/j.ophtha.2020.07.060
Okada M, Wong TY, Mitchell P, Eldem B, Talks SJ, Aslam T, et al. Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration. JAMA Ophthalmology. 2021;139:769–76.
doi: 10.1001/jamaophthalmol.2021.1660
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.
doi: 10.1056/NEJMoa054481
Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, et al. Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620–7.
doi: 10.1016/j.jfo.2014.11.015
Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251:1281–4.
doi: 10.1007/s00417-012-2177-3
Reiter GS, Grechenig C, Vogl W-D, Guymer RH, Arnold JJ, Bogunovic H, et al. Analysis of fluid volume and its impact on visual acuity in the fluid study as quantified with deep learning. Retina. 2021;41:1318–28.
pubmed: 33230065
Yoshida I, Sakamoto M, Sakai A, Maeno T. Effect of the duration of intraretinal or subretinal fluid on the response to treatment in undertreated age-related macular degeneration. J Ophthalmol. 2020;2020:e5308597.
Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina (Philadelphia, Pa). 2018;38:2293–300.
doi: 10.1097/IAE.0000000000001892
Wang X-X, Lin W-Q, Chen X-J, Lin Y-Y, Huang L-L, Zhang S-C, et al. Multimorbidity associated with functional independence among community-dwelling older people: a cross-sectional study in Southern China. Health Qual Life Outcomes [Internet]. 2017 [cited 2019 Feb 6];15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392938/
Angermann R, Rauchegger T, Nowosielski Y, Casazza M, Bilgeri A, Ulmer H, et al. Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol. 2019;257:2119–25.
doi: 10.1007/s00417-019-04414-y
Rauchegger T, Angermann R, Meusburger A, Schwab J, Haas G, Kralinger M, et al. Patient mobility and journey distance as risk factors for severe visual impairment: real-life data analysis of treatment-naïve patients with nAMD under intravitreal aflibercept therapy. Klin Monbl Augenheilkd. 2020;237:789–96.
doi: 10.1055/a-1008-9357
Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med. 2020;3:1–10.
doi: 10.1038/s41746-020-0277-8
Stattin M, Ahmed D, Graf A, Haas A-M, Kickinger S, Jacob M, et al. The effect of treatment discontinuation during the COVID-19 pandemic on visual acuity in exudative neovascular age-related macular degeneration: 1-year results. Ophthalmol Ther. 2021;2:2.
Borrelli E, Grosso D, Vella G, Sacconi R, Battista M, Querques L, et al. Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic. Graefes Arch Clin Exp Ophthalmol. 2020;258:2621–8.
doi: 10.1007/s00417-020-04955-7
Yeter DY, Dursun D, Bozali E, Ozec AV, Erdogan H. Effects of the COVID-19 pandemic on neovascular age-related macular degeneration and response to delayed Anti-VEGF treatment. J Fr Ophtalmol. 2021;44:299–306.
doi: 10.1016/j.jfo.2021.02.001
Teo KYC, Nguyen V, Barthelmes D, Arnold JJ, Gillies MC, Cheung CMG. Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence. Eye. 2020;2:1–9.
Sekeroglu MA, KilincHekimsoy H, HorozogluCeran T, Doguizi S. Treatment of neovascular age related macular degeneration during COVID-19 pandemic: The short term consequences of unintended lapses. Eur J Ophthalmol. 2021;2:2.
Soares RR, Mellen P, Garrigan H, Obeid A, Wibbelsman TD, Borkar D, et al. Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retina. 2020;4:134–40.
doi: 10.1016/j.oret.2019.07.010
Downer SR, Meara JG, Da Costa AC. Use of SMS text messaging to improve outpatient attendance. Med J Aust. 2005;183:366–8.
doi: 10.5694/j.1326-5377.2005.tb07085.x
Starr MR, Barkmeier AJ, Engman SJ, Kitzmann A, Bakri SJ. Telemedicine in the management of exudative age-related macular degeneration within an integrated health care system. Am J Ophthalmol. 2019;208:206–10.
doi: 10.1016/j.ajo.2019.03.021
Perepelkina T, Fulton AB. Artificial intelligence (AI) applications for age-related macular degeneration (AMD) and other retinal dystrophies. Semin Ophthalmol. 2021;36:304–9.
doi: 10.1080/08820538.2021.1896756